US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology Market Research Reports & Industry Analysis

RSS Feeds

CNS/Neurology Industry Research & Market Reports

3  4  5  6    8    10  11  12  
Market Highlights: Germany Glioblastoma – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, glioblastoma drugs market share, glioblastoma drugs sales estimates, glioblastoma drugs sales forecast, and glioblastoma late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: France Glioblastoma – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, glioblastoma drugs market share, glioblastoma drugs sales estimates, glioblastoma drugs sales forecast, and glioblastoma late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: US Glioblastoma – 2014
5/1/2014 | published by: Fore Pharma
... the US glioblastoma market size estimates for 2013, market share forecast for six years to 2019, glioblastoma drugs market share, glioblastoma drugs sales estimates, glioblastoma drugs sales forecast, and glioblastoma late stage pipeline products.This research ...  |  read more...
USD 990
Market Highlights: Europe Glioblastoma – 2014
5/1/2014 | published by: Fore Pharma
... research includes Europe (Germany, France, Italy, Spain, and UK) glioblastoma market size estimates for 2013, market share forecast for six years to 2019, glioblastoma drugs market share, glioblastoma drugs sales estimates, glioblastoma drugs sales forecast, ...  |  read more...
USD 2,800
Update: Schizophrenia Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing ...  |  read more...
USD 590
Update: Glioblastoma Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing ...  |  read more...
USD 590
Update: Amyotrophic Lateral Sclerosis Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... It covers emerging therapies for Amyotrophic Lateral Sclerosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating ...  |  read more...
USD 590
Update: Attention Deficit Hyperactivity Disorder Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... Hyperactivity Disorder market. It covers emerging therapies for Attention Deficit Hyperactivity Disorder in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking ...  |  read more...
USD 590
Update: Bipolar Disorder Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... therapies for Bipolar Disorder in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development ...  |  read more...
USD 590
Update: Neuroblastoma Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing ...  |  read more...
USD 590
Update: Opioid Addiction Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... therapies for Opioid Addiction in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development ...  |  read more...
USD 590
MediPoint: Neurovascular Interventions - APAC Analysis and Market Forecasts
4/30/2014 | published by: GlobalData
... interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices. The APAC neurovascular interventions ...  |  read more...
USD 4,450
Market Highlights: France Depression – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, depression drugs market share, depression drugs sales estimates, depression drugs sales forecast, and depression late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Japan Depression – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, depression drugs market share, depression drugs sales estimates, depression drugs sales forecast, and depression late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Europe Depression – 2014
5/1/2014 | published by: Fore Pharma
... research includes Europe (Germany, France, Italy, Spain, and UK) depression market size estimates for 2013, market share forecast for six years to 2019, depression drugs market share, depression drugs sales estimates, depression drugs sales forecast, ...  |  read more...
USD 2,800
Market Highlights: Spain Migraine – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, migraine drugs market share, migraine drugs sales estimates, migraine drugs sales forecast, and migraine late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Japan Migraine – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, migraine drugs market share, migraine drugs sales estimates, migraine drugs sales forecast, and migraine late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Europe Migraine – 2014
5/1/2014 | published by: Fore Pharma
... research includes Europe (Germany, France, Italy, Spain, and UK) migraine market size estimates for 2013, market share forecast for six years to 2019, migraine drugs market share, migraine drugs sales estimates, migraine drugs sales forecast, ...  |  read more...
USD 2,800
Market Highlights: Spain Bipolar Disorder – 2014
5/1/2014 | published by: Fore Pharma
... research includes Spain bipolar disorder market size estimates for 2013, market share forecast for six years to 2019, bipolar disorder drugs market share, bipolar disorder drugs sales estimates, bipolar disorder drugs sales forecast, and bipolar ...  |  read more...
USD 990
Market Highlights: US Bipolar Disorder – 2014
5/1/2014 | published by: Fore Pharma
... US. The research includes the US bipolar disorder market size estimates for 2013, market share forecast for six years to 2019, bipolar disorder drugs market share, bipolar disorder drugs sales estimates, bipolar disorder drugs sales ...  |  read more...
USD 990
Autism Global Clinical Trials Review, H1, 2014
5/30/2014 | published by: GlobalData
... relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  read more...
USD 2,500
PharmaPoint: Major Depressive Disorder - Current and Future Players
5/30/2014 | published by: GlobalData
... with in-depth analysis on the companies in the rapidly growing Major Depressive Disorder Market. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight ...  |  read more...
USD 2,995
PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such ...  |  read more...
USD 6,995
Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
3  4  5  6    8    10  11  12